valproic acid has been researched along with Neurodevelopmental Disorders in 10 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the general population, it is well established that periconceptual folic acid reduces the risk of neural tube defects (NTDs) and possibly other congenital abnormalities." | 5.05 | Valproate and folate: Congenital and developmental risks. ( Green, R; Reynolds, EH, 2020) |
| " Exposure to the antiepileptic drug valproic acid (VPA) during pregnancy significantly increases the risk of ASD in humans, and consequently is utilized as a validated animal model of ASD in rodents; however, the precise molecular and cellular mechanisms remain ill-defined." | 4.02 | Abnormal spatiotemporal expression pattern of progranulin and neurodevelopment impairment in VPA-induced ASD rat model. ( Chen, D; Hu, Y; Lan, J; Li, Y; Liao, A; Wang, S; Wang, X; Wang, Y; Yang, F; Zheng, W, 2021) |
| " A dose-response relationship was demonstrated and the risk of NDs was more particularly increased for an exposure to VPA during the second or third trimesters of pregnancy." | 1.56 | Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. ( Blotiere, PO; Coste, J; Dray-Spira, R; Mikaeloff, Y; Miranda, S; Peyre, H; Ramus, F; Weill, A; Zureik, M, 2020) |
| "Ataxia was observed in 7/34 cases." | 1.48 | Defining the phenotypic spectrum of SLC6A1 mutations. ( Abi-Warde, MT; Afenjar, A; Bird, LM; Carvill, GL; Chae, JH; Chelly, J; Choi, M; Christensen, J; Courage, C; Czapansky-Beilman, D; de Saint Martin, A; Devinsky, O; Doummar, D; Dubbs, H; Gardella, E; Gleeson, JG; Helbig, I; Helbig, KL; Hopkins, S; Johannesen, KM; Keren, B; Lehesjoki, AE; Lesca, G; Linnankivi, T; Mecarelli, O; Mefford, HC; Merritt, JL; Mignot, C; Millichap, JJ; Myers, CT; Møller, RS; Nava, C; Nespeca, M; Pal, DK; Pendziwiat, M; Pisani, L; Piton, A; Reichert, SC; Rodan, LH; Rubboli, G; Schaefer, E; Schelhaas, HJ; Shaw, JE; Specchio, N; Striano, P; Tan, WH; Tang, S; Trivisano, M; Verhoeven, JS; Weber, YG; Yoo, Y, 2018) |
| "Medulloblastoma is the most common malignant brain tumor in children." | 1.43 | Successful Use of Dose Dense Neoadjuvant Chemotherapy and Sodium Valproate with Minimal Toxicity in an Infant with Medulloblastoma in Extremely Poor General Condition. ( Abrari, A; Gupta, A; Kumar, A; Patir, R; Vaishya, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reynolds, EH | 1 |
| Green, R | 1 |
| Coste, J | 1 |
| Blotiere, PO | 1 |
| Miranda, S | 1 |
| Mikaeloff, Y | 1 |
| Peyre, H | 1 |
| Ramus, F | 1 |
| Zureik, M | 1 |
| Weill, A | 1 |
| Dray-Spira, R | 1 |
| Brotzmann, K | 1 |
| Wolterbeek, A | 1 |
| Kroese, D | 1 |
| Braunbeck, T | 1 |
| Lan, J | 1 |
| Hu, Y | 1 |
| Wang, X | 1 |
| Zheng, W | 1 |
| Liao, A | 1 |
| Wang, S | 1 |
| Li, Y | 1 |
| Wang, Y | 1 |
| Yang, F | 1 |
| Chen, D | 1 |
| Gobshtis, N | 1 |
| Tfilin, M | 1 |
| Wolfson, M | 1 |
| Fraifeld, VE | 1 |
| Turgeman, G | 1 |
| Johannesen, KM | 1 |
| Gardella, E | 1 |
| Linnankivi, T | 1 |
| Courage, C | 1 |
| de Saint Martin, A | 1 |
| Lehesjoki, AE | 1 |
| Mignot, C | 1 |
| Afenjar, A | 1 |
| Lesca, G | 1 |
| Abi-Warde, MT | 1 |
| Chelly, J | 1 |
| Piton, A | 1 |
| Merritt, JL | 1 |
| Rodan, LH | 1 |
| Tan, WH | 1 |
| Bird, LM | 1 |
| Nespeca, M | 1 |
| Gleeson, JG | 1 |
| Yoo, Y | 1 |
| Choi, M | 1 |
| Chae, JH | 1 |
| Czapansky-Beilman, D | 1 |
| Reichert, SC | 1 |
| Pendziwiat, M | 1 |
| Verhoeven, JS | 1 |
| Schelhaas, HJ | 1 |
| Devinsky, O | 1 |
| Christensen, J | 1 |
| Specchio, N | 1 |
| Trivisano, M | 1 |
| Weber, YG | 1 |
| Nava, C | 1 |
| Keren, B | 1 |
| Doummar, D | 1 |
| Schaefer, E | 1 |
| Hopkins, S | 1 |
| Dubbs, H | 1 |
| Shaw, JE | 1 |
| Pisani, L | 1 |
| Myers, CT | 1 |
| Tang, S | 2 |
| Pal, DK | 1 |
| Millichap, JJ | 1 |
| Carvill, GL | 1 |
| Helbig, KL | 1 |
| Mecarelli, O | 1 |
| Striano, P | 1 |
| Helbig, I | 1 |
| Rubboli, G | 1 |
| Mefford, HC | 1 |
| Møller, RS | 1 |
| Olsen, DB | 1 |
| Baftiu, A | 1 |
| Kumar, P | 1 |
| Mohan, V | 1 |
| Sinha, RA | 1 |
| Chagtoo, M | 1 |
| Godbole, MM | 1 |
| Gupta, A | 1 |
| Kumar, A | 1 |
| Abrari, A | 1 |
| Patir, R | 1 |
| Vaishya, S | 1 |
| Zieminska, E | 1 |
| Lenart, J | 1 |
| Lazarewicz, JW | 1 |
1 review available for valproic acid and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Valproate and folate: Congenital and developmental risks.
Topics: Anticonvulsants; Brain; Female; Folic Acid; Humans; Nervous System Malformations; Neural Tube Defect | 2020 |
9 other studies available for valproic acid and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France.
Topics: Adult; Anticonvulsants; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Epilepsy | 2020 |
Neurotoxic effects in zebrafish embryos by valproic acid and nine of its analogues: the fish-mouse connection?
Topics: Animals; Ecotoxicology; Embryo, Nonmammalian; Lethal Dose 50; Mice; Models, Biological; Morphogenesi | 2021 |
Abnormal spatiotemporal expression pattern of progranulin and neurodevelopment impairment in VPA-induced ASD rat model.
Topics: Animals; Anticonvulsants; Apoptosis; Autism Spectrum Disorder; Behavior, Animal; Brain; Disease Mode | 2021 |
Transplantation of mesenchymal stem cells reverses behavioural deficits and impaired neurogenesis caused by prenatal exposure to valproic acid.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Doublecortin Protein; Female; GABA Agents; Hi | 2017 |
Defining the phenotypic spectrum of SLC6A1 mutations.
Topics: Adolescent; Adult; Anticonvulsants; Ataxia; Child; Child, Preschool; Cohort Studies; Electroencephal | 2018 |
Valproate is contraindicated in pregnancy.
Topics: Anticonvulsants; Contraindications, Drug; Epilepsy; Female; Humans; Neurodevelopmental Disorders; Pr | 2019 |
Histone deacetylase inhibition reduces hypothyroidism-induced neurodevelopmental defects in rats.
Topics: Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Cerebellum; Co-Repressor Proteins; Dis | 2015 |
Successful Use of Dose Dense Neoadjuvant Chemotherapy and Sodium Valproate with Minimal Toxicity in an Infant with Medulloblastoma in Extremely Poor General Condition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Child; Child, Pre | 2016 |
Select putative neurodevelopmental toxins modify SNAP-25 expression in primary cultures of rat cerebellar granule cells.
Topics: Animals; Cells, Cultured; Cerebellum; Exocytosis; Gene Expression Regulation; Metal Nanoparticles; N | 2016 |